Drug news
Lyxumia (Sanofi-Aventis) is filed at EMA for Type 2 Diabetes
Lyxumia ( lixisenatide )from Sanofi Aventis a GLP-1 agonistis filed at EMA as monotherapy and as add-on to other anti diabetes medications, including Lantus.The application is supported by the Get Goal series of nine trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.